- Home
- ICU vs PHIO Comparison
ICU vs PHIO Comparison
Compare ICU & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- PHIO
- Stock Information
- Founded
- ICU 2018
- PHIO 2011
- Country
- ICU United States
- PHIO United States
- Employees
- ICU N/A
- PHIO N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- PHIO Health Care
- Exchange
- ICU Nasdaq
- PHIO Nasdaq
- Market Cap
- ICU 10.4M
- PHIO 11.9M
- IPO Year
- ICU N/A
- PHIO N/A
- Fundamental
- Price
- ICU $0.61
- PHIO $2.32
- Analyst Decision
- ICU
- PHIO Strong Buy
- Analyst Count
- ICU 0
- PHIO 2
- Target Price
- ICU N/A
- PHIO $9.00
- AVG Volume (30 Days)
- ICU 19.2M
- PHIO 200.0K
- Earning Date
- ICU 08-12-2025
- PHIO 08-13-2025
- Dividend Yield
- ICU N/A
- PHIO N/A
- EPS Growth
- ICU N/A
- PHIO N/A
- EPS
- ICU N/A
- PHIO N/A
- Revenue
- ICU $428,000.00
- PHIO N/A
- Revenue This Year
- ICU $754.07
- PHIO N/A
- Revenue Next Year
- ICU $100.09
- PHIO N/A
- P/E Ratio
- ICU N/A
- PHIO N/A
- Revenue Growth
- ICU N/A
- PHIO N/A
- 52 Week Low
- ICU $0.31
- PHIO $0.97
- 52 Week High
- ICU $9.56
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- ICU 41.48
- PHIO 55.02
- Support Level
- ICU $0.52
- PHIO $2.33
- Resistance Level
- ICU $0.83
- PHIO $2.62
- Average True Range (ATR)
- ICU 0.16
- PHIO 0.15
- MACD
- ICU 0.04
- PHIO 0.00
- Stochastic Oscillator
- ICU 50.89
- PHIO 65.69
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.